Gilead Sciences (XSWX:GILD) Cyclically Adjusted Book per Share: CHF15.29 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GILD Gilead Sciences Inc XSWX:GILD
69 GF Score
Price CHF106.02
GF Value CHF78.37
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Cyclically Adjusted Book per Share?

Gilead Sciences XSWX:GILD -0.39% 69 Cyclically Adjusted Book per Share is CHF15.29 as of Mar. 2026. GuruFocus rates XSWX:GILD with a GF Score™ of 69/100 and a GF Value™ of CHF78.37. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Gilead Sciences's adjusted book value per share for the three months ended in Mar. 2026 was CHF14.906. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is CHF15.29 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Gilead Sciences's average Cyclically Adjusted Book Growth Rate was 4.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 5.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 8.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Gilead Sciences was 29.80% per year. The lowest was 2.40% per year. And the median was 23.40% per year.

As of today (2026-07-15), Gilead Sciences's current stock price is CHF106.02. Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was CHF15.29. Gilead Sciences's Cyclically Adjusted PB Ratio of today is 6.93.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Gilead Sciences was 15.10. The lowest was 3.56. And the median was 5.95.


Gilead Sciences  (XSWX:GILD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Gilead Sciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=106.02/15.29
=6.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Gilead Sciences was 15.10. The lowest was 3.56. And the median was 5.95.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Gilead Sciences Cyclically Adjusted Book per Share Related Terms


Gilead Sciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Cyclically Adjusted Book per Share Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Gilead Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 15.29

XSWX:GILD vs PFE, AMGN, BMY: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PB Ratio falls into.


XSWX:GILD
69GF Score
Gilead Sciences Inc XSWX:GILD
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=14.906/330.2130*330.2130
=14.906

Current CPI (Mar. 2026) = 330.2130.

Gilead Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201606 11.316 241.018 15.504
201609 12.418 241.428 16.985
201612 14.697 241.432 20.101
201703 15.663 243.801 21.215
201706 16.810 244.955 22.661
201709 18.296 246.819 24.478
201712 15.425 246.524 20.661
201803 15.016 249.554 19.869
201806 16.555 251.989 21.694
201809 17.107 252.439 22.378
201812 16.547 251.233 21.749
201903 17.239 254.202 22.394
201906 17.643 256.143 22.745
201909 16.122 256.759 20.734
201912 17.483 256.974 22.466
202003 16.881 258.115 21.596
202006 13.676 257.797 17.518
202009 12.738 260.280 16.160
202012 12.895 260.474 16.347
202103 14.052 264.877 17.518
202106 14.263 271.696 17.335
202109 15.787 274.310 19.004
202112 15.474 278.802 18.327
202203 14.757 287.504 16.949
202206 15.656 296.311 17.447
202209 16.362 296.808 18.204
202212 15.868 296.797 17.655
202303 15.571 301.836 17.035
202306 15.276 305.109 16.533
202309 16.097 307.789 17.270
202312 15.847 306.746 17.059
202403 12.498 312.332 13.214
202406 13.115 314.175 13.784
202409 12.561 315.301 13.155
202412 13.829 315.605 14.469
202503 13.600 319.799 14.043
202506 12.882 322.561 13.188
202509 13.807 324.800 14.037
202512 14.582 324.054 14.859
202603 14.906 330.213 14.906

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of CHF15.29 mean?
Gilead Sciences (XSWX:GILD) has a Cyclically Adjusted Book per Share of CHF15.29 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Cyclically Adjusted Book per Share too high?
Gilead Sciences' current Cyclically Adjusted Book per Share is CHF15.29. Overall, Gilead Sciences has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Cyclically Adjusted Book per Share compare to PFE and AMGN?
Gilead Sciences' Cyclically Adjusted Book per Share of CHF15.29 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Cyclically Adjusted Book per Share is CHF15.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Gilead Sciences (XSWX:GILD) has a current Cyclically Adjusted Book per Share of CHF15.29. The stock's GF Value™ is CHF78.37, compared to a current price of CHF106.02 — trading 35.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is CHF15.29. Gilead Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Gilead Sciences (XSWX:GILD), the current Cyclically Adjusted Book per Share is CHF15.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (XSWX:GILD) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of CHF106.02 is trading 35.3% above its estimated GF Value™ of CHF78.37.

Key valuation signals for XSWX:GILD:

  • Cyclically Adjusted Book per Share: CHF15.29
  • GF Value™: CHF78.37 vs. price of CHF106.02 (35.3% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the XSWX:GILD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
69GF Score

Get the complete analysis for XSWX:GILD

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF106.02
Price
CHF78.37
GF Value